Navigation Links
Uroplasty Reports Fiscal Third Quarter 2013 Financial Results
Date:1/24/2013

ice President, CFO, and Treasurer

952.426.6140 EVC Group

Jenifer Kirtland (Investors)

415.568.4887

Chris Gale (Media)

646.201.5431  

UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited)Three Months EndedNine Months EndedDecember 31December 312012201120122011Net sales

$5,590,431$5,344,188$16,877,394$14,964,932Cost of goods sold 

734,171776,5382,264,7212,245,440Gross profit

4,856,2604,567,65014,612,67312,719,492Operating expenses  General and administrative

1,058,558924,5243,178,2392,888,939  Research and development

533,867586,4391,695,8411,499,070  Selling and marketing

3,725,5303,902,95211,424,40711,366,969  Amortization

215,681215,164646,971641,5355,533,6365,629,07916,945,45816,396,513Operating loss

(677,376)(1,061,429)(2,332,785)(3,677,021)Other income (expense)  Interest income

12,32714,26835,83645,818  Interest expense

(12)-(12)(57)  Foreign currency exchange gain (loss)

445(11,025)(3,432)(14,304)12,7603,24332,39231,457Loss before income taxes

(664,616)(1,058,186)(2,300,393)(3,645,564)Income tax expense 

12,7089,35235,81231,768Net loss

$(677,324)$(1,067,538)$(2,336,205)$(3,677,332)Basic and diluted loss per common share

$(0.03)$(0.05)$(0.11)$(0.18)Weighted average common shares outstanding:Basic and diluted

20,798,99720,718,34720,768,63220,678,865 

UROPLASTY, INC. AND SUBSIDIARIESCONDENSED CONSOLIDATED BALANCE SHEETS(Unaudited)December 31, 2012March 31, 2012AssetsCurrent assets:Cash and cash equivalents & short-term investments

$14,423,486$11,854,127Accounts receivable, net

2,463,5722,704,434Inventories

835,153698,742Other

433,790363,639Total current assets

18,156,00115,620,942Property, plant, and equipment, net


'/>"/>

SOURCE Uroplasty, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related medicine technology :

1. Uroplasty To Participate In The Oppenheimer 23rd Annual Healthcare Conference
2. Uroplasty To Participate In Two Upcoming Investor Conferences
3. Uroplasty Reports Fiscal Second Quarter 2013 Financial Results
4. Uroplasty To Participate In Two Upcoming Conferences
5. Uroplasty Reports Fiscal First Quarter 2013 Financial Results
6. Uroplasty to Issue First Quarter of Fiscal 2013 Financial Results on July 26, 2012
7. Uroplasty To Present At The JMP Securities Healthcare Conference
8. Uroplasty Reports Fiscal Fourth Quarter And Full Year 2012 Financial Results
9. Uroplasty Announces Product Development and New Clinical Trial Initiatives
10. Uroplasty to Present at the 11th Annual JMP Securities Research Conference
11. Cepheid Reports Fourth Quarter And Full Year 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2014)... N.C. , Aug. 1, 2014  With monumental ... learning to speak a second language. Clinical efficacy is ... agencies established under the ACA like PCORI are directing ... a variety of new entities and environments, the federal ... speak the new language of outcomes and managed markets ...
(Date:8/1/2014)... WASHINGTON , Aug. 1, 2014 In ... of treatments for sexual dysfunction, more than 60 doctors ... penned an open letter questioning the Food and Drug ... the most common form of male sexual dysfunction compared ... on the agency to act for women by approving ...
(Date:8/1/2014)... According to the new ... Anti infective), Basic (Films, Cleansing), Advanced (Hydrogels, Hydrocolloids, ... Pressure Relief Devices, NPWT) - Global Forecast to ... is expected to reach $18.3 Billion by 2019 ... CAGR of 3.2% from 2014 to 2019. ...
Breaking Medicine Technology:Pharmaceuticals Learning the Language of the New Healthcare Landscape 2Pharmaceuticals Learning the Language of the New Healthcare Landscape 360+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 260+ Doctors and Leading Medical Experts Sign an Open Letter Urging the FDA to Approve First-Ever Drug to Treat Women's Most Common Form of Sexual Dysfunction, notes Even the Score 3Wound Care Market Worth $18.3 Billion by 2019 2Wound Care Market Worth $18.3 Billion by 2019 3
... Banner Health and ... jointly announce Banner Health,s system-wide conversion to Masimo rainbow® SET ... Health hospital will be cared for using the most technologically ... "The decision to convert our entire hospital system ...
... 2, 2010 ... ... var shortURL = ... so we need to grab the first one. for (var r in data.results) { first_result = data.results[r]; ...
Cached Medicine Technology:Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 2Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 3Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 4Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 5Banner Health Converts 23-Hospital System to Masimo rainbow SET Technology 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 2Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 3Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 4Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 5Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 6Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 7Manufacturing of Biologics - Increasing Demand for Monoclonal Antibodies and Recombinant Proteins Drives Increases in Capacities and Innovative Production Technologies Now Available at ReportsandReports 8
(Date:8/1/2014)... plays a central role in regulating appetite and whole-body ... the brain,s control of food intake and body weight, ... has been unclear. A new study in ... PPARγ activity in a type of neuron known as ... to high-fat diet. Sabrina Diano and colleagues at ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 Stryker ... wake of the 2012 Rejuvenate and ABG II ... in New Jersey’s Bergen County Superior Court, Bernstein ... the proceeding, the Court has issued a ... any and all hard copy and electronic materials ...
(Date:8/1/2014)... at University Hospitals Rainbow Babies & Children,s Hospital (UH ... risk for death on a commercial airline flight. The ... January 2010 and June 2013 and found 90 percent ... 2. , The study was conducted in partnership ... in-flight pediatric fatality onboard commercial airline flights worldwide. Through ...
(Date:8/1/2014)... (PRWEB) August 01, 2014 The ... for independent community pharmacies. At ThoughtSpot 2014, AmerisourceBergen ... equipped with practices and resources to enhance patient ... leaders focused on critical issues to give independent ... and grow. , ThoughtSpot show attendance experienced ...
(Date:8/1/2014)... of a cancer diagnosis may improve health outcomes for ... by a researcher at the University of Houston (UH). ... intervention is the writing instruction. Otherwise, writing is just ... journal can be therapeutic, but oftentimes we don,t get ... not," said Qian Lu, assistant professor and director of ...
Breaking Medicine News(10 mins):Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 2Health News:Stryker Hip Lawsuit News: New Order Issued in New Jersey Stryker Hip Recall Litigation, Bernstein Liebhard LLP Reports 3Health News:New research characterizes in-flight pediatric deaths 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 2Health News:ThoughtSpot 2014 Inspires as General Session Concludes 3Health News:ThoughtSpot 2014 Inspires as General Session Concludes 4Health News:ThoughtSpot 2014 Inspires as General Session Concludes 5Health News:Expressive writing may help breast cancer survivors 2Health News:Expressive writing may help breast cancer survivors 3
... Blood donors with hemochromatosis, a disorder in which iron ... a greater risk to blood safety than other donors, ... the National Heart, Lung, and Blood Institute (NHLBI). // ... or "blood letting" to remove excess iron from their ...
... Researchers at Harvard Medical School have looked at the use ... They find that the use of 20 therapies - from ... 1960s. A new survey reveals that complementary and alternative medicine ... has changed over the years. // ...
... heart disease can expect to live longer if they take ... for people with a high risk of stroke or heart ... - preventing clotting - and also reduces inflammation. A new ... US now reveals that aspirin reduces deaths from all causes ...
... found a cheap and non toxic method of treating Hepatitis, ... virus infects the liver, and in severe cases can lead ... through contact with the blood or body fluids of an ... HBV after a very bright and aware patient observed that ...
... heal wounds made inside the body during surgery without scarring. ... stops tissues sticking together to form painful scars. One of ... be used ,during keyhole surgery, which is now commonly preferred ... made from polyethylene glycol, is now undergoing clinical trials in ...
... relief for chronic pain, and should be studied for ... conference in Glasgow.,Dr William Notcutt of the James Paget ... used in his study - applied as a spray ... chronic pain. He announced the findings at the annual ...
Cached Medicine News:
Microalbumin Linearity Control...
Total IgE Control...
The K-ASSAY Lipid Controls are assayed controls produced from fresh human sera to monitor the accuracy and precision of quantitative lipid determinations of human sera specimens....
The K-ASSAY hs-CRP Control Set is intended to be used as a consistent test sample of known concentrations for monitoring the performance of hs-CRP (high sensitive C-Reactive Protein) immunoturbimetri...
Medicine Products: